CA2921805C - Tgf-beta receptor type ii variants and uses thereof - Google Patents

Tgf-beta receptor type ii variants and uses thereof Download PDF

Info

Publication number
CA2921805C
CA2921805C CA2921805A CA2921805A CA2921805C CA 2921805 C CA2921805 C CA 2921805C CA 2921805 A CA2921805 A CA 2921805A CA 2921805 A CA2921805 A CA 2921805A CA 2921805 C CA2921805 C CA 2921805C
Authority
CA
Canada
Prior art keywords
seq
amino acid
polypeptide
fibrosis
gdf15
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2921805A
Other languages
English (en)
French (fr)
Other versions
CA2921805A1 (en
Inventor
Ravindra Kumar
Asya Grinberg
Dianne S. Sako
Roselyne CASTONGUAY
Rita Steeves
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acceleron Pharma Inc
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of CA2921805A1 publication Critical patent/CA2921805A1/en
Application granted granted Critical
Publication of CA2921805C publication Critical patent/CA2921805C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
CA2921805A 2013-08-22 2014-08-21 Tgf-beta receptor type ii variants and uses thereof Active CA2921805C (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201361868713P 2013-08-22 2013-08-22
US61/868,713 2013-08-22
US201361906270P 2013-11-19 2013-11-19
US61/906,270 2013-11-19
US201361906849P 2013-11-20 2013-11-20
US61/906,849 2013-11-20
PCT/US2014/052130 WO2015027082A1 (en) 2013-08-22 2014-08-21 Tgf-beta receptor type ii variants and uses thereof

Publications (2)

Publication Number Publication Date
CA2921805A1 CA2921805A1 (en) 2015-02-26
CA2921805C true CA2921805C (en) 2023-03-07

Family

ID=52480573

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2921805A Active CA2921805C (en) 2013-08-22 2014-08-21 Tgf-beta receptor type ii variants and uses thereof

Country Status (8)

Country Link
US (6) US20150056199A1 (cg-RX-API-DMAC7.html)
EP (2) EP3705498A1 (cg-RX-API-DMAC7.html)
JP (4) JP2016528295A (cg-RX-API-DMAC7.html)
CN (2) CN116655801A (cg-RX-API-DMAC7.html)
AU (2) AU2014308751B2 (cg-RX-API-DMAC7.html)
CA (1) CA2921805C (cg-RX-API-DMAC7.html)
HK (2) HK1225742A1 (cg-RX-API-DMAC7.html)
WO (1) WO2015027082A1 (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
CU24446B1 (es) 2013-03-13 2019-10-04 Prothena Biosciences Ltd Un anticuerpo monoclonal humanizado que se une a tau
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
EP3174550B1 (en) * 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
US10603359B2 (en) 2014-10-30 2020-03-31 Acceleron Pharma Inc. Methods and compositions using GDF15 polypeptides for increasing red blood cells
JP7055636B2 (ja) 2015-04-06 2022-04-18 アクセルロン ファーマ インコーポレイテッド ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
JP6810702B2 (ja) 2015-04-06 2021-01-06 アクセルロン ファーマ インコーポレイテッド シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
KR101706462B1 (ko) * 2015-07-09 2017-02-14 부산대학교 산학협력단 Nag-1 억제제를 유효성분으로 포함하는 난소암 환자의 항암제 내성 억제용 약학조성물
EP3331550B1 (en) * 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
WO2017152105A1 (en) * 2016-03-04 2017-09-08 Ngm Biopharmaceuticals, Inc. Compositions and methods for modulating body weight
BR112018072394A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem a tau
ES2933491T3 (es) 2016-05-02 2023-02-09 Prothena Biosciences Ltd Inmunoterapia tau
US10889638B2 (en) 2016-05-02 2021-01-12 Prothena Biosciences Limited Antibodies recognizing tau
PE20190117A1 (es) 2016-05-24 2019-01-16 Novo Nordisk As Compuestos de mic-1 y usos de estos
AU2017336546C1 (en) 2016-09-27 2025-05-29 Epicentrx, Inc. Immunomodulatory fusion proteins
KR102761094B1 (ko) 2016-10-05 2025-02-03 악셀레론 파마 인코포레이티드 변이체 actriib 단백질 및 이의 용도
JOP20190100A1 (ar) * 2016-11-19 2019-05-01 Potenza Therapeutics Inc بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
KR20190111058A (ko) * 2017-01-25 2019-10-01 테사 테라퓨틱스 피티이. 엘티디. TGF-β 디코이 수용체
AU2018228435C1 (en) 2017-03-02 2025-09-18 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
US11958896B2 (en) 2017-05-02 2024-04-16 Prothena Biosciences Limited Antibodies recognizing tau
FI3628049T3 (fi) * 2017-05-04 2023-07-26 Acceleron Pharma Inc Tgf-beeta-reseptorin tyypin ii fuusioproteiineja ja niiden käyttöjä
US11274142B2 (en) 2017-05-12 2022-03-15 Jiangsu Hengrui Medicine Co., Ltd. Fusion protein containing TGF-β receptor and medicinal uses thereof
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
AU2018338612A1 (en) 2017-09-27 2020-05-07 Epicentrx, Inc. Immunomodulatory fusion proteins
JP7348899B2 (ja) 2017-12-08 2023-09-21 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性分子及びその使用
EP3737692A4 (en) 2018-01-09 2021-09-29 Elstar Therapeutics, Inc. CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES
US12364736B2 (en) 2018-02-09 2025-07-22 Acceleron Pharma Inc. Methods for treating heterotopic ossification
BR112020017382A2 (pt) 2018-03-09 2021-01-26 Agenus Inc. anticorpos anti-cd73 e métodos de uso dos mesmos
US20210009711A1 (en) 2018-03-14 2021-01-14 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
EP3765517A1 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
WO2019213446A1 (en) * 2018-05-03 2019-11-07 Acceleron Pharma Inc. NOVEL BINDERS OF TGFβ-SUPERFAMILY LIGANDS AND USES THEREOF
EP3810645A1 (en) 2018-06-22 2021-04-28 Kite Pharma, Inc. Chimeric transmembrane proteins and uses thereof
AU2019297451A1 (en) 2018-07-03 2021-01-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3105750A1 (en) 2018-07-09 2020-01-16 Precigen, Inc. Fusion constructs and methods of using thereof
CN109097461B (zh) * 2018-09-06 2021-07-30 北京中关村生命科学园生物医药科技孵化有限公司 一种心肌病相关基因检测试剂及其应用
AU2019346645A1 (en) 2018-09-27 2021-04-29 Marengo Therapeutics, Inc. CSF1R/CCR2 multispecific antibodies
MX2021005018A (es) * 2018-11-09 2021-06-15 Jiangsu Hengrui Medicine Co Composicion farmaceutica de proteina de fusion del receptor tgf-?, y uso de la misma.
WO2020172605A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Antibody molecules that bind to nkp30 and uses thereof
CN114127112A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 与t细胞结合的多功能分子及其治疗自身免疫性病症的用途
CA3130754A1 (en) 2019-02-21 2020-08-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
PE20212324A1 (es) 2019-03-03 2021-12-14 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN114391021A (zh) 2019-06-21 2022-04-22 凯德药业股份有限公司 TGF-β受体和使用方法
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
JP7495489B2 (ja) 2019-10-21 2024-06-04 ナンチン リーズ バイオラブス カンパニー，リミティド ＰＤ－１およびＴＧＦβを標的化する組換えタンパク質
MX2022004873A (es) 2019-10-23 2022-05-13 Cue Biopharma Inc Polipeptidos de tgf-?.
WO2021092079A1 (en) * 2019-11-05 2021-05-14 Acceleron Pharma Inc. Treatments for systemic sclerosis
TWI772984B (zh) * 2019-11-27 2022-08-01 大陸商上海岸邁生物科技有限公司 TGFβ/PD-L1雙特異性結合蛋白
GB2609554B (en) 2020-01-03 2025-08-20 Marengo Therapeutics Inc Anti-TCR antibody molecules and uses thereof
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
GB2612450A (en) 2020-04-24 2023-05-03 Marengo Therapeutics Inc Multifunctional molecules that bind to T cell related cancer cells and uses thereof
EP4144764A4 (en) * 2020-04-28 2024-07-17 Sinocelltech Ltd. TRUNCATED EXTRACELLULAR DOMAIN MOLECULE TGFßR2, FUSION PROTEIN OF TRUNCATED EXTRACELLULAR DOMAIN MOLECULE TGFßR2 AND ANTI-EGFR ANTIBODY, AND ANTITUMORAL USE OF FUSION PROTEIN
CN113754777A (zh) * 2020-06-02 2021-12-07 三生国健药业（上海）股份有限公司 一种抗PD-L1/TGF-β融合蛋白
AU2021305234A1 (en) 2020-07-10 2023-02-09 Precigen, Inc. Fusion constructs and methods of using thereof
US11028174B1 (en) 2020-07-28 2021-06-08 Lepu Biopharma Co., Ltd. Bifunctional molecules targeting PD-L1 and TGF-β
JP2023539645A (ja) 2020-08-26 2023-09-15 マレンゴ・セラピューティクス，インコーポレーテッド Ｎｋｐ３０に結合する抗体分子およびその使用
AU2021331075A1 (en) 2020-08-26 2023-04-06 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
AU2021333779A1 (en) 2020-08-26 2023-04-13 Marengo Therapeutics, Inc. Methods of detecting TRBC1 or TRBC2
CN112215941B (zh) * 2020-09-04 2021-06-25 北京科技大学 一种基于微分几何的主动脉扭曲的评估方法及系统
WO2022068894A1 (zh) * 2020-09-30 2022-04-07 上海齐鲁制药研究中心有限公司 同时靶向pd-l1和vegf的双功能分子及其医药用途
WO2022105751A1 (zh) * 2020-11-19 2022-05-27 信达生物制药(苏州)有限公司 TGFβRII融合蛋白以及其用途
US20240000891A1 (en) * 2020-12-08 2024-01-04 The Board Of Trustees Of The Leland Stanford Junior University Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
US20240277807A1 (en) * 2021-06-11 2024-08-22 Acceleron Pharma Inc. Actrii proteins and uses thereof
TW202328173A (zh) * 2021-09-02 2023-07-16 大陸商廣東菲鵬製藥股份有限公司 中國廣東省東莞市松山湖園區桃園路1號10棟301室 郵編：523808 TGFβRII突變體及其應用
CA3243129A1 (en) 2022-01-28 2023-08-03 35Pharma Inc. Type IIB Activin Receptor Variants and Their Uses
JP2024096518A (ja) * 2023-01-03 2024-07-16 エフビーデー バイオロジクス リミテッド 操作されたｔｇｆｂｒｉｉバリアント及びその使用方法
EP4653010A1 (en) 2024-05-14 2025-11-26 35Pharma Inc. Activin receptor type iib traps for use in improving body composition

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8529014D0 (en) 1985-11-25 1986-01-02 Biogen Nv Enhanced secretion of heterologous proteins
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
IL98569A0 (en) 1990-06-20 1992-07-15 Bristol Myers Squibb Co Pharmaceutical compositions containing tgf-b and antagonists thereof for modulating blood pressure
GB9106678D0 (en) 1991-03-28 1991-05-15 Ferguson Mark W J Wound healing
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
CA2122491A1 (en) 1991-10-31 1993-05-13 Herbert Y. Lin Tgf-.beta. type receptor cdnas and uses therefor
US5543143A (en) 1992-03-06 1996-08-06 Corixa Corporation Method for activating macrophages/monocytes
JPH08504763A (ja) * 1992-10-29 1996-05-21 セルトリックス ファーマシューティカルズ，インコーポレイテッド 治療薬としてのＴＧＦ−βレセプターフラグメントの使用
US5677196A (en) 1993-05-18 1997-10-14 University Of Utah Research Foundation Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
JPH09503673A (ja) 1993-10-14 1997-04-15 プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ ニューロン細胞の誘導および維持法
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
US5525490A (en) 1994-03-29 1996-06-11 Onyx Pharmaceuticals, Inc. Reverse two-hybrid method
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5814565A (en) 1995-02-23 1998-09-29 University Of Utah Research Foundation Integrated optic waveguide immunosensor
US5866323A (en) 1995-04-07 1999-02-02 Case Western Reserve University Cancer diagnosis prognosis and therapy based on mutation of receptors for transforming growth factor β and homologous growth controlling factors
DE69636866D1 (en) 1995-04-11 2007-03-15 Gen Hospital Corp Reverse "two-hybrid"-systeme
US6423501B2 (en) 1996-12-13 2002-07-23 Beth Israel Deaconess Medical Center Calcium-independent negative regulation by CD81 of receptor signaling
EP0975771B1 (en) * 1997-04-18 2007-07-11 Biogen Idec MA Inc. Type ii tgf-beta receptor/immunoglobulin constant region fusion proteins
AU7467898A (en) 1997-04-21 1998-11-13 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial cr signal and induce clonal anergy
US6294350B1 (en) 1997-06-05 2001-09-25 Dalhousie University Methods for treating fibroproliferative diseases
ZA988461B (en) 1997-09-18 1999-03-30 Idec Pharma Corp Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
IL138608A0 (en) 1998-04-02 2001-10-31 Genentech Inc Antibody variants and fragments thereof
AU4572899A (en) 1998-06-16 2000-01-05 Biogen, Inc. Variant type ii tgf-beta receptor fusion proteins and methods
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
WO2001066140A1 (en) 2000-03-09 2001-09-13 Genzyme Corporation Use of tgf-beta antagonists to treat or to prevent loss of renal function
AU2001249446A1 (en) 2000-03-24 2001-10-08 Dzgenes, L.L.C. Diagnostic polymorphisms of tgf-beta-rii promoter
US20030028905A1 (en) 2001-07-31 2003-02-06 Petra Knaus Mutant forms of the TGF-beta type II receptor which bind all TGF-beta isoforms
JP4564261B2 (ja) 2002-01-22 2010-10-20 ジェンザイム、コーポレーション 慢性的移植片拒絶反応の治療と予防のためのＴＧＦ−β拮抗薬の使用
US7919084B2 (en) 2002-06-17 2011-04-05 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
CA2513086A1 (en) 2002-12-19 2004-07-08 Scios Inc. Treatment of obesity and associated conditions with tgf-.beta. inhibitors
WO2004098637A1 (en) 2003-04-30 2004-11-18 Genzyme Corporation Tgf-beta antagonists combined with renin-angiotensin-aldosteron-system antagonists for treating renal insufficiency
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
NZ545544A (en) 2003-08-13 2009-04-30 Univ Illinois Silencing of TGF-beta receptor type II expression by sirna
CA2536293A1 (en) 2003-08-22 2005-03-03 Boehringer Ingelheim Pharmaceuticals, Inc. Methods of treating copd and pulmonary hypertension
US20090042780A1 (en) 2004-05-20 2009-02-12 Acceleron Pharma Inc Modified TGF-Beta Superfamily Polypeptides and Related Methods
MXPA06014126A (es) * 2004-06-04 2007-07-18 Regeneron Pharma Metodos para utilizar antagonistas il-1 para tratar enfermedades auto-inflamatorias.
US7786261B2 (en) 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
EP1796715A2 (en) 2004-09-22 2007-06-20 Genzyme Corporation USE OF TGF-ß ANTAGONISTS TO LIMIT NEPHROTOXICITY OF IMMUNOSUPPRESSIVE AGENTS
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
EP1809324A4 (en) 2004-10-13 2009-02-25 Univ Ohio State Res Found METHOD FOR TREATING OR PREVENTING VIRAL LMPMPHOPROIBLE DISEASES
TR201901929T4 (tr) 2005-02-08 2019-03-21 Genzyme Corp TGFBeta'ya antikorlar.
JP5342834B2 (ja) 2008-09-05 2013-11-13 日東電工株式会社 骨髄線維症処置剤
ITMI20060181A1 (it) 2006-02-03 2007-08-04 Univ Padova Modulatori del tgf-b e loro uso
WO2007108992A2 (en) 2006-03-13 2007-09-27 The Johns Hopkins University Augmentation of endothelial thromboresistance
EP2029625A2 (en) 2006-06-05 2009-03-04 Novartis AG Use of tgf-beta antagonists in treatment of parathyroid-related disorders
EP2083863B1 (en) 2006-10-03 2015-03-18 Genzyme Corporation Antibodies to tgf-beta for use in the treatment of infants at risk of developing bronchopulmonary dysplasia
EP2140005B1 (en) 2007-03-19 2013-12-11 National Research Council of Canada Fusion proteins comprising two tgf-beta binding domains
WO2008157367A1 (en) 2007-06-15 2008-12-24 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
ATE520682T1 (de) 2007-08-22 2011-09-15 Irm Llc 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren
JP2011509676A (ja) 2008-01-18 2011-03-31 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド ヒトＴｈ１７細胞の選択的分化、同定および調節
KR20180029111A (ko) * 2008-05-02 2018-03-19 악셀레론 파마 인코포레이티드 혈관신생 및 혈관주위세포 적용범위의 조정을 위한 ａｌｋ１ 길항제 기재의 방법 및 조성물
WO2009143309A2 (en) 2008-05-21 2009-11-26 Trustees Of Dartmouth College Female reproductive tract and anal prophylaxes
WO2009152610A1 (en) 2008-06-20 2009-12-23 The Royal Institution For The Advancement Of Learning/Mcgill University Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof
US20100015144A1 (en) * 2008-06-26 2010-01-21 Acceleron Pharma Inc. Methods for dosing an activin-actriia antagonist and monitoring of treated patients
JP2011526794A (ja) * 2008-07-02 2011-10-20 エマージェント プロダクト デベロップメント シアトル， エルエルシー ＴＧＦ−βアンタゴニスト多重標的結合性分子
EP2326670A4 (en) * 2008-09-17 2014-04-16 Nat Res Council Canada HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
WO2010048273A2 (en) 2008-10-21 2010-04-29 President And Fellows Of Harvard College Methods and compounds for treatment of neurodegenerative disorders
AU2010204985A1 (en) 2009-01-13 2011-08-04 Acceleron Pharma Inc. Methods for increasing adiponectin
CA2757095C (en) * 2009-03-30 2020-04-14 Acceleron Pharma Inc. Bmp-alk3 antagonists and uses for promoting bone growth
WO2010129515A1 (en) 2009-05-08 2010-11-11 The United Satates Of America As Represented By The Secretary, Department Of Health & Human Services Modulation of the tgf-beta and pi3k/akt pathways in the diagnosis and treatment of squamous cell carcinoma
US20110172296A1 (en) 2010-01-12 2011-07-14 Bennett C Frank Modulation of transforming growth factor-beta 1 expression
US8993524B2 (en) * 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CN101852804B (zh) * 2010-03-29 2013-06-12 中国医学科学院病原生物学研究所 Gdf15蛋白的抗体的新用途
US8080568B1 (en) 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
KR101939965B1 (ko) 2010-09-01 2019-01-18 젠자임 코포레이션 ＴＧＦ－β 길항제를 이용한 심근경색증의 치료
US20130287688A1 (en) 2010-11-18 2013-10-31 Xtuit Pharmaceuticals, Inc. Novel compositions and uses of anti-hypertension agents for cancer therapy
US8800906B2 (en) 2010-12-27 2014-08-12 The Board Of Trustees Of The Leland Stanford Junior University Use of transforming growth factor-beta neutralizing antibodies and fusion proteins thereof in treating pain
WO2012093125A1 (en) 2011-01-06 2012-07-12 Glaxo Group Limited Ligands that bind tgf-beta receptor ii
CN108341863A (zh) 2011-04-20 2018-07-31 阿塞勒隆制药公司 内皮糖蛋白多肽及其用途
CN102850458B (zh) * 2011-06-28 2014-10-01 华博生物医药技术（上海）有限公司 新型重组双功能融合蛋白及其制法和用途
WO2013012648A1 (en) * 2011-07-15 2013-01-24 Emory University Gdf15 in diagnostic and therapeutic applications
CA2843535C (en) 2011-08-01 2021-04-06 Tufts Medical Center, Inc. Treatment of cardiac diseases and fibrosis with endoglin receptor antibodies and antigen-binding fragments thereof
AU2013202269A1 (en) 2011-10-26 2013-05-16 Howard Florey Institute Of Experimental Physiology And Medicine Compositions and methods for the treatment of fibrosis and fibrotic diseases
EP3333183B1 (en) 2012-04-30 2023-02-22 Biocon Limited Targeted/immunomodulatory fusion proteins and methods for making same
HK1208361A1 (en) 2012-05-16 2016-03-04 Aadigen, Llc Multi-target modulation for treating fibrosis and inflammatory conditions
HUE042020T2 (hu) 2013-03-11 2019-06-28 Genzyme Corp Génmódosított anti-TGF-béta ellenanyagok és antigénkötõ fragmensek
CA3081073C (en) 2013-03-12 2023-09-12 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
CN105452287A (zh) 2013-04-17 2016-03-30 贝勒医学院 免疫抑制性TGF-β信号转换器
HK1225742A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma, Inc. TGF-β受体II型变体及其用途
EP4005585B1 (en) 2013-11-21 2024-03-27 The Brigham & Women's Hospital, Inc. Compositions and methods for treating right ventricular hypertrophy
JP6731346B2 (ja) 2014-02-10 2020-07-29 メルク パテント ゲーエムベーハー 標的ＴＧＦβ阻害
CN113817672A (zh) 2014-05-18 2021-12-21 儿童医学中心公司 涉及外排体的方法和组合物
CA2952061A1 (en) 2014-06-13 2015-12-17 Novartis Ag Use of serelaxin to reduce gdf-15
EP3174550B1 (en) 2014-08-01 2020-01-29 The Brigham and Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
JP7055636B2 (ja) 2015-04-06 2022-04-18 アクセルロン ファーマ インコーポレイテッド ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用
EP3331550B1 (en) 2015-08-04 2022-11-02 Acceleron Pharma Inc. Composition for treating myeloproliferative disorders
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
WO2017134592A1 (en) 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
CN109641963A (zh) 2016-08-12 2019-04-16 默克专利有限公司 癌症的联合治疗
AU2017336546C1 (en) 2016-09-27 2025-05-29 Epicentrx, Inc. Immunomodulatory fusion proteins
WO2018129331A1 (en) 2017-01-07 2018-07-12 Merck Patent Gmbh Dosing regimens and dosage forms for targeted tgf-b inhibition
AU2018228435C1 (en) 2017-03-02 2025-09-18 National Research Council Of Canada TGF-beta-receptor ectodomain fusion molecules and uses thereof
FI3628049T3 (fi) 2017-05-04 2023-07-26 Acceleron Pharma Inc Tgf-beeta-reseptorin tyypin ii fuusioproteiineja ja niiden käyttöjä
US12364736B2 (en) 2018-02-09 2025-07-22 Acceleron Pharma Inc. Methods for treating heterotopic ossification

Also Published As

Publication number Publication date
AU2020203514A1 (en) 2020-06-18
AU2014308751A1 (en) 2016-03-17
EP3036262A1 (en) 2016-06-29
JP2019194270A (ja) 2019-11-07
WO2015027082A1 (en) 2015-02-26
US9809637B2 (en) 2017-11-07
HK1225740A1 (zh) 2017-09-15
CA2921805A1 (en) 2015-02-26
US20160376341A1 (en) 2016-12-29
US11008377B2 (en) 2021-05-18
HK1225742A1 (zh) 2017-09-15
JP2024015040A (ja) 2024-02-01
US10316076B2 (en) 2019-06-11
US20180179261A1 (en) 2018-06-28
US20210230252A1 (en) 2021-07-29
US20150056199A1 (en) 2015-02-26
US10981973B2 (en) 2021-04-20
AU2020203514B2 (en) 2022-06-16
JP2021112212A (ja) 2021-08-05
JP2016528295A (ja) 2016-09-15
US20200157182A1 (en) 2020-05-21
AU2014308751B2 (en) 2020-03-05
EP3036262A4 (en) 2017-03-01
CN116655801A (zh) 2023-08-29
EP3705498A1 (en) 2020-09-09
CN105658672A (zh) 2016-06-08
US20190284257A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
CA2921805C (en) Tgf-beta receptor type ii variants and uses thereof
US12144860B2 (en) ALK1 receptor and ligand antagonists and uses thereof
AU2019232838B2 (en) Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage
EP3628049B1 (en) Tgf-beta receptor type ii fusion proteins and uses thereof
US20090304691A1 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
US20220017600A1 (en) Methods and compositions for modulating angiogenesis and pericyte composition
CA2724525A1 (en) Antagonists of bmp9, bmp10, alk1 and other alk1 ligands, and uses thereof
HK40037295A (en) Tgf-beta receptor type ii variants and uses thereof
HK40025678B (en) Tgf-beta receptor type ii fusion proteins and uses thereof
HK40025678A (en) Tgf-beta receptor type ii fusion proteins and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190821

EEER Examination request

Effective date: 20190821

EEER Examination request

Effective date: 20190821

EEER Examination request

Effective date: 20190821

EEER Examination request

Effective date: 20190821

EEER Examination request

Effective date: 20190821